Vera Therapeutics, Inc.

We're kicking off a series of features on the talented and experienced leaders of Vera, starting with the newest addition to our team: Matt Skelton, EVP of Commercial. Matt's industry expertise will be invaluable as our organization prepares for potential commercialization. Learn more about our leadership team: https://lnkd.in/eCD_xbpt

We're looking forward to presenting the latest findings from the Phase 2b ORIGIN clinical trial in #IgANephropathy at the upcoming American Society of Nephrology #KidneyWk 2024 in San Diego. Don't miss our late breaking oral presentation of long-term ORIGIN results on Saturday Oct 26, and be sure to visit us at booth 2321! Details on our presentations here: https://lnkd.in/eSf74f5s

Today we held our second R&D Day this year to announce our expanded atacicept development program in multiple autoimmune kidney diseases. We're excited to explore the disease-modifying potential of atacicept in new indications. For more information, read the press release (https://lnkd.in/d-V8NgAS) and watch the webcast (https://lnkd.in/dUaphXhu).?

We're excited to announce that the ORIGIN Phase 2b clinical data of atacicept in #IgANephropathy have been recognized as a finalist for the Scrip Awards' Clinical Advance of the Year! We're grateful to the investigators, study team members, and most importantly, the participants who made the trial possible. Read more about the trial here: https://lnkd.in/eRcDMqd5

Don't forget to register for our in-person and virtual R&D Day in New York on October 2! We're presenting our potential indication expansion for atacicept beyond the ORIGIN Phase 2b and Phase 3 clinical program in #IgANephropathy. Our management team will be joined by Dr. Jonathan Barratt, Richard Lafayette, and Brad Rovin. Read the full press release: https://lnkd.in/e-732r8q $VERA

Don't miss our fireside chat on September 18 at 9:10 AM ET at the 2024 Cantor Global Healthcare Conference. Watch the webcast here: https://lnkd.in/eUtRwa8N $VERA

Join us for our in-person and virtual R&D Day in New York on October 2, where we will present our expanded atacicept R&D activities outside of the ORIGIN Phase 2b and Phase 3 clinical program in #IgANephropathy. Our management team will be joined by Dr. Jonathan Barratt, Richard Lafayette, and Brad Rovin. Read the full press release: https://lnkd.in/e-732r8q $VERA

We completed enrollment of 200 participants for the primary endpoint of our pivotal ORIGIN 3 Phase 3 clinical trial of atacicept in #IgAN! Thank you to all the investigators, study staff, and participants for helping us enroll ahead of schedule. We look forward to presenting topline results in Q2 2025, with long-term 96-week data from the ORIGIN Phase 2b clinical trial coming in Q4 2024. Read the release for more information: https://lnkd.in/eVSkhXv5 #IgANephropathy

We're grateful to have such talented and motivated individuals on Team Vera and we're proud to recognize their hard work. Congratulations to everyone who earned a promotion and thank you all for your dedication! Learn more about life at Vera: https://lnkd.in/e-pnxz8D

Next week we're attending the Wells Fargo Healthcare Conference in Boston, where we will host one-on-one investor meetings on Thursday September 5, 2024. Learn about our participation at upcoming investor conferences: https://lnkd.in/ecWgRnGn $VERA